Treatment of Dementia-Related Psychosis in Hospital Settings

Introduction to Treatment Approaches

• The American Geriatrics Society recommends immediately implementing non-pharmacological interventions using the DICE approach for dementia-related psychosis in hospital settings, reserving antipsychotic medications for emergency situations such as psychosis causing harm, major depression with suicidal ideation, or aggression causing risk to self or others 1

Immediate Assessment and Investigation

• The American Geriatrics Society suggests screening for infections, particularly urinary tract infections and pneumonia, as these are major contributors to behavioral disturbances in patients who cannot verbally communicate discomfort 2, 3
• Assessment for dehydration, constipation, and uncontrolled pain is crucial as these frequently precipitate psychotic symptoms 2, 3
• Reviewing all medications for anticholinergic effects or other agents that may worsen hallucinations and delusions is necessary 2, 3

First-Line: Non-Pharmacological Interventions

• The American Geriatrics Society, American Psychiatric Society, and American Association for Geriatric Psychiatry recommend non-pharmacological strategies as the preferred first-line treatment approach, except in emergency situations when psychosis could lead to imminent danger 4
• Optimizing lighting levels to reduce visual misinterpretations and removing mirrors or reflective surfaces that can trigger hallucinations is recommended 2, 3
• Minimizing ambiguous visual stimuli and ensuring adequate bright light exposure during daytime to regulate circadian rhythms is suggested 2
• Reducing nighttime light and noise to create favorable sleep environments is advised 2
• Using calm tones, simple single-step commands, and gentle touch for reassurance rather than complex multi-step instructions is recommended 2, 3
• Avoiding harsh tones, open-ended questions, and confrontational approaches as these escalate agitation is necessary 2, 3
• Allowing adequate time for the patient to process information before expecting a response is crucial 5

Second-Line: Pharmacological Treatment

• Psychotropic medications should only be used after significant efforts are made to mitigate symptoms using behavioral and environmental modifications, with three exceptions where medication may be used immediately: psychosis causing harm, major depression with suicidal ideation, or aggression causing risk to self or others 1
• For Lewy body dementia with visual hallucinations, cholinesterase inhibitors are the preferred pharmacological treatment, demonstrating specific efficacy for visual hallucinations in this population 2, 3
• For severe, persistent psychotic symptoms in Alzheimer's disease, consider atypical antipsychotics with extreme caution only after environmental manipulation and non-pharmacological approaches have failed 3
• Risperidone, olanzapine, and quetiapine may be considered for severe psychotic symptoms, but with careful monitoring of adverse effects 5

Critical Safety Discussion Required

• Before initiating any antipsychotic, discussing with the patient and surrogate decision maker the increased mortality risk, cardiovascular effects, cerebrovascular adverse reactions, and expected benefits and treatment goals is necessary 1, 5, 6

Monitoring and Reassessment Protocol

• Evaluating response within 30 days of initiating any psychotropic medication using quantitative measures is recommended 2, 3
• Monitoring closely for adverse effects such as extrapyramidal symptoms, metabolic changes, falls, and orthostatic hypotension is crucial 1, 5
• Considering tapering or discontinuing medications after 6 months of symptom stabilization, as behaviors and symptoms may resolve over time with or without drug treatment, is advised 1, 2

Critical Pitfalls to Avoid

• Not using antipsychotics for mild psychotic symptoms that are not causing distress or safety concerns is recommended 5
• Not continuing antipsychotics indefinitely without regular reassessment at every visit is necessary 5
• Not using typical antipsychotics as first-line therapy due to the risk of tardive dyskinesia is advised 5
• Not using benzodiazepines routinely due to the risk of tolerance, cognitive impairment, and paradoxical agitation is recommended 5
• Not underestimating pain and discomfort as causes of psychotic symptoms in patients who cannot verbally communicate is crucial 2
• Remembering that psychotropics are not likely to impact unfriendliness, poor self-care, memory problems, repetitive verbalizations, or wandering is necessary 6

Management of Psychosis in Dementia – Evidence‑Based Guideline

1. First‑Line Non‑Pharmacologic Approach

• Environmental and behavioral modifications must be attempted and documented as unsuccessful before any medication is considered, except in emergency situations. [American Geriatrics Society, JAGS 2014]7
• Installation of safety equipment (e.g., grab bars, removal of hazardous objects, designation of safe zones) reduces risk of injury and supports autonomy. [Alzheimer’s Association, Alzheimer’s & Dementia 2025]8

2. Communication & Structured Routines

• Use calm tone, simple one‑step commands, and allow ample processing time to minimize agitation. [Alzheimer’s Association, Alzheimer’s & Dementia 2025]8
• Provide predictable daily schedules and individualized structured activities that match the person’s abilities and prior interests. [Alzheimer’s Association, Alzheimer’s & Dementia 2025]8

3. Indications for Antipsychotic Use (Emergency Situations)

• Antipsychotics are reserved exclusively for:

4. Safety Discussion Prior to Initiating Antipsychotics

• Mortality risk is increased 1.6–1.7‑fold compared with placebo in elderly patients with dementia. [American Geriatrics Society, JAGS 2014]7
• Cardiovascular hazards include QT‑interval prolongation, arrhythmias, sudden death, and hypotension. [American Geriatrics Society, JAGS 2014]7
• Cerebrovascular adverse events such as stroke are more frequent. [American Geriatrics Society, JAGS 2014]7
• Typical antipsychotics should not be first‑line because they carry a ~50 % risk of tardive dyskinesia after two years of continuous use in older adults. [American Geriatrics Society, JAGS 2014]7
• Routine benzodiazepine use is discouraged; approximately 10 % of older adults develop tolerance, cognitive decline, or paradoxical agitation. [American Geriatrics Society, JAGS 2014]7

5. Pharmacologic Options for Severe Persistent Psychosis (Alzheimer’s Disease)

6. Monitoring, Reassessment, and Tapering

• Evaluate therapeutic response within 30 days (≈ 4 weeks) using quantitative behavioral scales. [American Geriatrics Society, JAGS 2014]7
• Conduct daily in‑person examinations to detect adverse effects (e.g., EPS, falls, metabolic changes, QT prolongation, cognitive worsening). [American Geriatrics Society, JAGS 2014]7
• After symptom stabilization, taper the antipsychotic over 3–6 months to determine ongoing necessity. [American Geriatrics Society, JAGS 2014]7

7. Pitfalls to Avoid

• Do not prescribe antipsychotics for mild psychotic symptoms that do not cause distress or safety concerns. [American Geriatrics Society, JAGS 2014]7
• Do not continue antipsychotics indefinitely; reassess at every clinical encounter and attempt tapering when appropriate. [American Geriatrics Society, JAGS 2014]7
• Recognize that psychotropic agents are unlikely to improve non‑psychotic behavioral issues such as unfriendliness, poor self‑care, memory deficits, repetitive verbalizations, or wandering. [American Geriatrics Society, JAGS 2014]7